Companies
Huangshan Tianmu Mint Pharmaceutical
subsidiary of the listed Tianmu Pharmaceutical group; received a renewed drug-manufacturing license from the Anhui Provincial Drug Administration (valid through December 31, 2030) covering raw-material-drug production of menthol and mint-sucrose oil.
- Country
- China
Anhui NMPA drug manufacturing license renewed to 2030
cn
Coverage
| CN | EU | |
|---|---|---|
| specialty-fine-chem | ✓ | ✓ |
Regulatorsreachnmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | CNY 50 million in funding expected from Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd. (2025-03-11) | marketscreener.com |
| Regulatory approval | Received renewed drug-manufacturing license from the Anhui Provincial Drug Administration, valid through 2030-12-31 (2025-10-24) | yaopinnet.com |
| Certification | GMP certification (Certificate No. 皖H0198) for menthol and peppermint oil production lines (2007-01-22) | yaopinnet.com |
| Production site | No. 1, Jiulong Avenue, Huangshan Jiulong Low Carbon Economic Park, Tunxi District, Huangshan City, Anhui Province (2006-12) | yaopinnet.com |
| Capacity | Annual processing capacity of 600 tons of raw oil, producing 330 tons of menthol and 240 tons of peppermint oil (2006-12) | yaopinnet.com |
Independent sources: marketscreener.com · yaopinnet.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic menthol | specialty-fine-chem | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.